Evidence map›Paper›PMID 35284557›Full record

ArticleAnnals of translational medicine2022

Integrated model for COVID-19 diagnosis based on computed tomography artificial intelligence, and clinical features: a multicenter cohort study.

Yuki Kataoka, Yuya Kimura, Tatsuyoshi Ikenoue, Yoshinori Matsuoka, Junichi Matsumoto, Junji Kumasawa, Kentaro Tochitatni, Hiraku Funakoshi, Tomohiro Hosoda, Aiko Kugimiya and 5 more

Abstract read
In one paragraph

Article in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yuki Kataoka *Department of Internal Medicine, Kyoto Min-Iren Asukai Hospital, Tanaka Asukai-cho, Kyoto, Japan.
Yuya Kimura *Clinical Research Center, Department of Respiratory Medicine, National Hospital Organization Tokyo National Hospital, Kiyose-shi, Tokyo, Japan.
Tatsuyoshi IkenoueHuman Health Sciences, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto, Japan.
Yoshinori MatsuokaDepartment of Healthcare Epidemiology, Kyoto University Graduate School of Medicine/Public Health, Sakyo-ku, Kyoto, Japan.
Junichi MatsumotoDepartment of Emergency and Critical Care Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
Junji KumasawaHuman Health Sciences, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto, Japan.
Kentaro TochitatniDepartment of Infectious Diseases, Kyoto City Hospital, Nakagyo-ku, Kyoto, Japan.
Hiraku FunakoshiDepartment of Emergency and Critical Care Medicine, Tokyobay Urayasu Ichikawa Medical Center, Urayasu, Chiba, Japan.
Tomohiro HosodaDepartment of Infectious Disease, Kawasaki Municipal Kawasaki Hospital, Kawasaki, Kanagawa, Japan.
Aiko KugimiyaDepartment of Emergency and Critical Care Medicine, Yamanashi Prefectural Central Hospital, Kofu, Yamanashi, Japan.
Michinori ShiranoDepartment of Infectious Diseases, Osaka City General Hospital, Miyakojima-ku, Osaka, Japan.
Fumiko HamabeDepartment of Radiology, National Defense Medical College Hospital, Tokorozawa, Saitama, Japan.
Sachiyo IwataDivision of Cardiovascular Medicine, Hyogo Prefectural Kakogawa Medical Center, Kanno-cho, Kakogawa, Japan.
Shingo FukumaHuman Health Sciences, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto, Japan.
Japan COVID-19 AI team*

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: We developed and validated a machine learning diagnostic model for the novel coronavirus (COVID-19) disease, integrating artificial-intelligence-based computed tomography (CT) imaging and clinical features. Methods: We conducted a retrospective cohort study in 11 Japanese tertiary care facilities that treated COVID-19 patients. Participants were tested using both real-time reverse transcription polymerase chain reaction (RT-PCR) and chest CTs between January 1 and May 30, 2020. We chronologically split the dataset in each hospital into training and test sets, containing patients in a 7:3 ratio. A Light Gradient Boosting Machine model was used for the analysis. Results: A total of 703 patients were included, and two models-the full model and the A-blood model-were developed for their diagnosis. The A-blood model included eight variables (the Ali-M3 confidence, along with seven clinical features of blood counts and biochemistry markers). The areas under the receiver-operator curve of both models [0.91, 95% confidence interval (CI): 0.86 to 0.95 for the full model and 0.90, 95% CI: 0.86 to 0.94 for the A-blood model] were better than that of the Ali-M3 confidence (0.78, 95% CI: 0.71 to 0.83) in the test set. Conclusions: The A-blood model, a COVID-19 diagnostic model developed in this study, combines machine-learning and CT evaluation with blood test data and performs better than the Ali-M3 framework existing for this purpose. This would significantly aid physicians in making a quicker diagnosis of COVID-19.

Indexed as

COVID-19decision support tooldiagnosisLight Gradient Boosting Machine (LightGBM)machine learning

Identifiers

PMID35284557
PMCPMC8904977

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.